Skip to content
  • Investor Relations
  • Careers
  • Galleri.com
Search
grail logo
grail logo
  • Galleri Test
    • The Test
    • The Science
      • Multi-Cancer Early Detection
      • Precision Oncology
    • The Stories
  • Clinical Expertise
    • Clinical Studies
    • Clinical Evidence
  • News + Media
    • News Center
    • Media Resources
    • Subscribe to Newsletter
  • About
    • Our Story
    • Leadership Team
    • Partnering
      • Overview
      • Biopharma Partnerships
      • Grants
      • External Sponsored Research
    • Working at GRAIL
    • Get in Touch
  • Investor Relations
  • Careers
  • Galleri.com
grail logo
grail logo
  • Galleri Test
    • The Test
    • The Science
      • Multi-Cancer Early Detection
      • Precision Oncology
    • The Stories
  • Clinical Expertise
    • Clinical Studies
    • Clinical Evidence
  • News + Media
    • News Center
    • Media Resources
    • Subscribe to Newsletter
  • About
    • Our Story
    • Leadership Team
    • Partnering
      • Overview
      • Biopharma Partnerships
      • Grants
      • External Sponsored Research
    • Working at GRAIL
    • Get in Touch
  • Investor Relations
  • Careers
  • Galleri.com

Prognostic significance of blood-based multi-cancer detection in circulating tumor DNA (ctDNA): 5-year outcomes analysis

By Grail Content Editor / May 31, 2025

View presentation

← Previous Presentation
Next Presentation →

grail logo
  • Privacy Notices
  • Terms of Service
  • ADA Accessibility Statement
  • California Notice at Collection
  • Quality and Regulatory
  • UK Modern Slavery Statement
  • Your California Privacy Choices
  • Cookie Notice and Choices
  • Non-Solicitation Statement
  • Purchase Terms
  • Social Media Community Guidelines
  • Subscribe to Our Newsletter

833-464-7245

Get in Touch

© 2026 GRAIL, Inc. All rights reserved. Galleri is a registered trademark of GRAIL, Inc. The information on this site is intended for audiences in the United States only.

back to top
TOP